Shuttle session: M2 Macrophage Suppression Assay for immunotherapeutic screening

04 / 09 / 2019

We are proud to offer a first in vitro shuttle session on our newly validated M2 macrophage suppression assay, which will take place early June, 2019 – thereby providing an opportunity to timely and cost-effectively assess novel immunotherapeutics.

Our M2 suppression assay, based on i) the co-culture of monocyte-derived M2 macrophages and activated CD4+ T cells and ii) the quantification of IFNg levels as surrogate of T cell activation, is specifically designed to assess candidate compounds for their potential to repolarize / switch M2 macrophages and to antagonize M2-mediated T cell suppression.

Contact us when it is still time to grab your seat!